How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials.
Abstract
We conducted a systematic review and meta-analysis of randomized controlled trials that compared second-generation antipsychotic (SGA) drugs with placebo in schizophrenic patients and which considered 13 different outcome measures. Thirty-eight randomized controlled trials with 7323 participants were included. All SGA drugs were more effective than placebo, but the pooled effect size (ES) for overall symptoms (primary outcome) was moderate (-0.51). The absolute difference (RD) in responder rates was at 18% (41% responded to drug compared with 24% to placebo, number needed to treat=6). Similar ESs were found for the other efficacy parameters: negative symptoms (ES=-0.39), positive symptoms (ES=-0.48), depression (ES=-0.26), relapse (RD 20%) and discontinuation due to inefficacy (RD 17%). Curiously, the efficacy of haloperidol for negative and depressive symptoms was similar to that of the SGA drugs. In contrast to haloperidol, there was no difference in terms of EPS between any SGA drugs and placebo, and there was also no difference in terms of dropouts due to adverse events. Meta-regression showed a decline in treatment response over time, and a funnel plot suggested the possibility of publication bias. We conclude that the drug versus placebo difference of SGA drugs and haloperidol in recent trials was moderate, and that there is much room for more efficacious compounds. Whether methodological issues account in part for the relatively low efficacy ESs and the scarcity of adverse event differences compared with placebo needs to be established.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Large-scale meta-analyses suggest that the effectiveness of antipsychotic and antidepressant medications is only marginally different from placebo, and neither has successfully remediated cognitive dysfunction.
“However, several large-scale meta-analyses have recently suggested that the effectiveness of antipsychotic and antidepressant medications is only marginally different from that of a placebo (Leucht et al., 2009; Rief et al., 2009), and neither have been able to successfully remediate cognitive dysfunction (Keefe et al., 2013, 2014; Solé et al., 2015).”
From Aerobic Exercise as a Tool to Improve Hippocampal Plasticity and Function in Humans: Practical Implications for Mental Health Treatment (2016) · cites this paper as Leucht et al., 2009
Cites
Statistical Power Analysis for the Behavioral Sciences
Muller, K. E., & Cohen, J. (1989) · Technometrics · doi:10.2307/1270020 · Cited by 99,588 · see citing works
Statistical power analysis for the behavioral sciences
Cohen, J. (1990) · Computers Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,406 · see citing works
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · see citing works
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722 · see citing works
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · see citing works
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048 · see citing works
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378 · see citing works
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090 · see citing works
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892 · see citing works
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
Simpson, G. M., B., M., B., G., Angus, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,265 · see citing works
Charbonneau, D. H. (2005) · Europe PMC (PubMed Central) · Cited by 2,041 · see citing works
Guy, W. L. (2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65186-5_300379 · Cited by 1,441 · see citing works
Risperidone in the treatment of schizophrenia
Marder, S. R., & Meibach, R. C. (1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.6.825 · Cited by 1,194 · see citing works
Geddes, J. R., Freemantle, N., Harrison, P. J., & Bebbington, P. (2000) · BMJ · doi:10.1136/bmj.321.7273.1371 · Cited by 1,060 · see citing works
Jones, P., Barnes, T., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R., Markwick, A., & Lewis, S. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,060 · see citing works
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,035 · see citing works
(2004) · The Lancet · doi:10.1016/s0140-6736(04)16499-4 · Cited by 892 · see citing works
Chouinard, G., Jones, B., Remington, G. J., BLOOM, D., Addington, D. E., MacEwan, G. W., Labelle, A., Beauclair, L., & Arnott, W. S. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199302000-00004 · Cited by 876 · see citing works
Arvanitis, L. A., & Miller, B. G. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00190-x · Cited by 806 · see citing works
Leucht, S., Pitschel‐Walz, G., Abraham, D., & Kissling, W. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00105-4 · Cited by 795 · see citing works
Olanzapine versus Placebo and Haloperidol
Beasley, C. M., Tollefson, G. D., Tran, P., SATTERLEE, W. G., Sanger, T. M., & Hamilton, S. H. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00069-p · Cited by 777 · see citing works
Rummel‐Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C. A., Kissling, W., Davis, J. M., & Leucht, S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.07.012 · Cited by 679 · see citing works
Kane, J. M., Carson, W. H., Saha, A. R., McQuade, R. D., Ingenito, G. G., ZIMBROFF, D. L., & Ali, M. W. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0903 · Cited by 624 · see citing works
Potkin, S. G., Saha, A. R., Kujawa, M. J., Carson, W. H., Ali, M. W., Stock, E. G., Stringfellow, J., Ingenito, G. G., & Marder, S. R. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.7.681 · Cited by 592 · see citing works
[The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use].
Boissel, J., Cucherat, M., Li, W., Châtellier, G., Gueyffier, F., Buyse, M. E., Boutitie, F., Nony, P., Haugh, M., & Mignot, G. (1999) · PubMed · Cited by 533 · see citing works
Leucht, S., Komossa, K., Rummel‐Kluge, C., Corves, C., Hunger, H., Schmid, F., Lobos, C. A., Schwarz, S., & Davis, J. M. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030368 · Cited by 489 · see citing works
Quetiapine in Patients With Schizophrenia
Small, J. G. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830180067009 · Cited by 482 · see citing works
Predictors of Treatment Response From a First Episode of Schizophrenia or Schizoaffective Disorder
Robinson, D. G., Woerner, M. G., Alvir, J. M. J., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D. I., Bilder, R. M., GOLDMAN, R. S., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.4.544 · Cited by 466 · see citing works
Heres, S., Davis, J. M., Maino, K., Jetzinger, E., Kissling, W., & Leucht, S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.185 · Cited by 447 · see citing works
Neuroleptic Withdrawal in Schizophrenic Patients
Gilbert, P. L. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150005001 · Cited by 434 · see citing works
Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial
Beasley, C. M., Sanger, T. M., SATTERLEE, W. G., Tollefson, G. D., Tran, P., & Hamilton, S. H. (1996) · Psychopharmacology · doi:10.1007/bf02245617 · Cited by 390 · see citing works
'Akinetic Depression' in Schizophrenia
Putten, T. V. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770330075006 · Cited by 386 · see citing works
Daniel, D. G. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00090-6 · Cited by 377 · see citing works
Lieberman, J. A., Phillips, M. R., Gu, H., Stroup, T. S., Zhang, P., Kong, L., Zhong-fu, J., Koch, G. G., & Hamer, R. M. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300157 · Cited by 346 · see citing works
Linking the PANSS, BPRS, and CGI: Clinical Implications
Leucht, S., Kane, J. M., Etschel, E., Kissling, W., Hamann, J., & Engel, R. R. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301147 · Cited by 333 · see citing works
Efficacy of antidepressants in adults
Moncrieff, J., & Kirsch, I. (2005) · BMJ · doi:10.1136/bmj.331.7509.155 · Cited by 329 · see citing works
Guttmacher, M. S. (1964) · PubMed · Cited by 310 · see citing works
Aripiprazole for the Prevention of Relapse in Stabilized Patients With Chronic Schizophrenia
Pigott, T. A., Carson, W. H., Saha, A. R., Torbeyns, A. F., Stock, E. G., Ingenito, G. G., & Aripiprazole Study Group (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0910 · Cited by 309 · see citing works
ZIMBROFF, D. L., Kane, J. M., Tamminga, C. A., Daniel, D. G., Mack, R. J., Wozniak, P. J., Sebree, T. B., Wallin, B., & Kashkin, K. B. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.6.782 · Cited by 306 · see citing works
Cheung, B. M. Y., Lauder, I. J., Lau, C., & Kumana, C. R. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2003.02060.x · Cited by 303 · see citing works
Numbers needed to treat derived from meta-analyses---sometimes informative, usually misleading
Smeeth, L. L., Haines, A., & Ebrahim, S. B. J. (1999) · BMJ · doi:10.1136/bmj.318.7197.1548 · Cited by 301 · see citing works
ICI 204,636, an Atypical Antipsychotic
Borison, R. L., Arvanitis, L. A., & Milier, B. G. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199604000-00008 · Cited by 272 · see citing works
Social Adversity, the Serotonin Transporter (5-HTTLPR) Polymorphism and Major Depressive Disorder
Surtees, P. G., Wainwright, N. W. J., Willis-Owen, S. A. G., Luben, R., Day, N. E., & Flint, J. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.014 · Cited by 265 · see citing works
Keck, P. E., Buffenstein, A., Ferguson, J. M., Feighner, J. P., Jaffe, W., Harrigan, E. P., & Morrissey, M. R. (1998) · Psychopharmacology · doi:10.1007/s002130050755 · Cited by 265 · see citing works
Haloperidol versus placebo for schizophrenia
Irving, C. B., Adams, C. E., & Lawrie, S. M. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003082.pub2 · Cited by 247 · see citing works
Scherk, H., Pajonk, F. G., & Leucht, S. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.4.442 · Cited by 243 · see citing works
Chlorpromazine versus placebo for schizophrenia
Adams, C. E., Awad, G. A., Rathbone, J., & Thornley, B. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000284.pub2 · Cited by 241 · see citing works
Treatment of Negative Symptoms in Schizophrenia with Amisulpride
Boyer, P., Lecrubier, Y., Puech, A. J., Dewailly, J., & Aubin, F. (1995) · The British Journal of Psychiatry · doi:10.1192/bjp.166.1.68 · Cited by 228 · see citing works
Risperidone: clinical safety and efficacy in schizophrenia.
Borison, R. L., Pathiraja, A., Diamond, B. I., & Meibach, R. C. (1992) · PubMed · Cited by 210 · see citing works
Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia
Lôo, H., Poirier, M. F., Theron, M., Rein, W., & Fleurot, O. (1997) · The British Journal of Psychiatry · doi:10.1192/bjp.170.1.18 · Cited by 195 · see citing works
Neuroleptic Withdrawal in Schizophrenic Patients
Baldessarini, R. J. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150021002 · Cited by 194 · see citing works
Improvement of Schizophrenic Patients With Primary Negative Symptoms Treated With Amisulpride
Danion, J., Rein, W., Fleurot, O., & the Amisulpride Study Group (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.4.610 · Cited by 185 · see citing works
Arató, M., Connor, R. O., & Meltzer, H. Y. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200209000-00001 · Cited by 178 · see citing works
Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time
Trikalinos, T. A., Churchill, R., Ferri, M., Leucht, S., Tuunainen, A., Wahlbeck, K., & Ioannidis, J. P. A. (2004) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.02.018 · Cited by 177 · see citing works
Self-citationChlorpromazine versus placebo for schizophrenia
Adams, C. E., Awad, G. A., Rathbone, J., Thornley, B., & Soares‐Weiser, K. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000284.pub3 · Cited by 167 · see citing works
A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia
van Kammen, D. P., McEvoy, J. P., Targum, S. D., Kardatzke, D. R., & Sebree, T. B. (1996) · Psychopharmacology · doi:10.1007/bf02245618 · Cited by 157 · see citing works
Haloperidol versus placebo for schizophrenia
Adams, C. E., Bergman, H., Irving, C. B., & Lawrie, S. M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003082.pub3 · Cited by 157 · see citing works
Improvement of some schizophrenic deficit symptoms with low doses of amisulpride
Martinot, M. P., Lecrubier, Y., Martinot, J., & Aubin, F. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.1.130 · Cited by 142 · see citing works
Selection Bias in Clinical Trials With Antipsychotics
Hofer, A., Hummer, M., Huber, R., Kurz, M., Walch, T., & Fleischhacker, W. W. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200012000-00019 · Cited by 112 · see citing works
Evil or Ill? Justifying the Insanity Defense
Robinson, G. E. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.10.1659 · Cited by 106 · see citing works
Corrigan, M. H. N., Gallen, C. C., Bonura, M. L., & Merchant, K. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.10.004 · Cited by 105 · see citing works
Potkin, S. G., Gharabawi, G. M., Greenspan, A. J., Mahmoud, R. A., Kosik‐Gonzalez, C., Rupnow, M. F. T., Bossie, C. A., Davidson, M., Burtea, V., & ZHU, Y. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.03.027 · Cited by 94 · see citing works
Fabre, L. F., Arvanitis, L. A., Pultz, J. A., Jones, V. M., Malick, J. B., & Slotnick, V. B. (1995) · Clinical Therapeutics · doi:10.1016/0149-2918(95)80102-2 · Cited by 92 · see citing works
Beasley, C. M., Sutton, V. K., Hamilton, S. H., Walker, D. J., Dossenbach, M. R. K., Taylor, C. C., Alaka, K., Bykowski, D., & Tollefson, G. D. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000095348.32154.ec · Cited by 87 · see citing works
Cooper, S. J., Tweed, J. A., Raniwalla, J., Butler, A., & Welch, C. P. (2000) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2000.101003218.x · Cited by 67 · see citing works
Riedel, M. J., Strassnig, M., M�ller, N., Zwack, P., & M�ller, H.-J. (2004) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-004-0547-5 · Cited by 60 · see citing works
Benign Breast Disease — The Risks of Communicating Risk
Elmore, J. G., & Gigerenzer, G. (2005) · New England Journal of Medicine · doi:10.1056/nejme058111 · Cited by 60 · see citing works
Cooper, S. J., Butler, A., Tweed, J. A., Welch, C. P., & Raniwalla, J. (2000) · Psychopharmacology · doi:10.1007/s002130000452 · Cited by 55 · see citing works
Cavazzoni, P. A., Berg, P. H., Kryzhanovskaya, L. A., Briggs, S. D., Roddy, T. E., Tohen, M. F., & Kane, J. M. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0116 · Cited by 49 · see citing works
Employment Characteristics of Discharged Schizophrenics
Cole, N. J. (1964) · Archives of General Psychiatry · doi:10.1001/archpsyc.1964.01720210096015 · Cited by 45 · see citing works
Risperidone for Severe Tardive Dyskinesia
Bai, Y., Yu, S.-C., & Lin, C.-C. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1110 · Cited by 45 · see citing works
Bai, Y., Yu, S.-C., & Lin, C.-C. (2003) · PubMed · Cited by 39 · see citing works
Möller, H. J., Riedel, M. J., Müller, N., Fischer, W., & Kohnen, R. (2004) · Pharmacopsychiatry · doi:10.1055/s-2004-832683 · Cited by 38 · see citing works
Cooper, S. J., Tweed, J., Raniwalla, J., et al. (2000) · Acta Psychiatrica Scandinavica · doi:10.1046/j.0902-4441.2000.ap90086.x · Cited by 33 · see citing works
Efficacy and safety of sertindole in a trial of schizophrenic patients
Zborowski, J. V., Schmitz, P., Staser, J., O'Neil, J., Giles, K., Wallin, B., Sebree, T. B., & Tamminga, C. A. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(95)94656-h · Cited by 18 · see citing works
Lecrubier, Y., Bouhassira, M., Olivier, V., Lancrenon, S., & Crawford, A. M. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)80345-9 · Cited by 14 · see citing works
Efficacy and safety of lower doses of aripiprazole
Modell, S., Werner, C., Spevakné-Göröcs, T., Kungel, M., & Ebrecht, M. (2005) · Pharmacopsychiatry · doi:10.1055/s-2005-918782 · Cited by 5 · see citing works
Efficacy of electroconvulsive therapy for depressive disorders in a Bavarian district hospital
Mueller, E., Stöhr, K., Weixler, C., Kuenzel, H., Schuld, A., & Pollmächer, T. (2005) · Pharmacopsychiatry · doi:10.1055/s-2005-918785 · Cited by 1 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561 · see citing works
Self-citationSecond-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930 · see citing works
International Consensus Study of Antipsychotic Dosing
Gardner, D. M., Murphy, A. L., O'Donnell, H., Centorrino, F., & Baldessarini, R. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09060802 · Cited by 1,302 · see citing works
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145 · see citing works
Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer‐Lindenberg, A., Weinberger, D. R., Cannon, T. D., O’Donovan, M. C., Correll, C. U., Kane, J. M., van Os, J., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.67 · Cited by 1,132 · see citing works
Correll, C. U., & Schooler, N. R. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s225643 · Cited by 911 · see citing works
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J. A., Glenthoj, B. Y., Gattaz, W. F., Thibaut, F., Möller, H., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637 · see citing works
Barnes, T. R. E., Drake, R., Paton, C., Cooper, S. J., Deakin, J. F. W., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I. R., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 607 · see citing works
Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies
Haddad, P. M., Brain, C., & Scott, J. L. (2014) · Patient Related Outcome Measures · doi:10.2147/prom.s42735 · Cited by 587 · see citing works
Leucht, S., Leucht, C., Huhn, M., Chaimani, A., Mavridis, D., Helfer, B., Samara, M., Rabaioli, M., Bächer, S., Cipriani, A., et al. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16121358 · Cited by 542 · see citing works
Self-citationLeucht, S., Komossa, K., Rummel‐Kluge, C., Corves, C., Hunger, H., Schmid, F., Lobos, C. A., Schwarz, S., & Davis, J. M. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030368 · Cited by 489 · see citing works
Leucht, S., Hierl, S., Kissling, W., Dold, M., & Davis, J. M. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.096594 · Cited by 451 · see citing works
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J. A., Glenthoj, B. Y., Gattaz, W. F., Thibaut, F., Möller, H., & WFSBP Task force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.739708 · Cited by 418 · see citing works
Kishimoto, T., Robenzadeh, A., Leucht, C., Leucht, S., Watanabe, K., Mimura, M., Borenstein, M., Kane, J. M., & Correll, C. U. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs150 · Cited by 395 · see citing works
Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.025 · Cited by 385 · see citing works
Dose Equivalents for Second-Generation Antipsychotics: The Minimum Effective Dose Method
Leucht, S., Samara, M. T., Heres, S., Patel, M. X., Woods, S. W., & Davis, J. M. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu001 · Cited by 373 · see citing works
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365 · see citing works
Kishimoto, T., Hagi, K., Kurokawa, S., Kane, J. M., & Correll, C. U. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00039-0 · Cited by 369 · see citing works
Barnes, T. R. E. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 357 · see citing works
Dudley, R., Taylor, P., Wickham, S., & Hutton, P. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv150 · Cited by 353 · see citing works
Huhn, M., Tardy, M., Spineli, L. M., Kissling, W., Förstl, H., Pitschel-Walz, G., Leucht, C., Samara, M., Dold, M., Davis, J. M., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.112 · Cited by 333 · see citing works
Sowing the seeds of doubt: a narrative review on metacognitive training in schizophrenia
Moritz, S., Andreou, C., Schneider, B. C., Wittekind, C. E., Menon, M., Balzan, R. P., & Woodward, T. S. (2014) · Clinical Psychology Review · doi:10.1016/j.cpr.2014.04.004 · Cited by 325 · see citing works
Schedlowski, M., Enck, P., Rief, W., & Bingel, U. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009423 · Cited by 323 · see citing works
Schoeler, T., Monk, A., Sami, M. B., Klamerus, E., Foglia, E., Brown, R., Camuri, G., Altamura, A. C., Murray, R., & Bhattacharyya, S. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00363-6 · Cited by 322 · see citing works
Dose Equivalents for Second-Generation Antipsychotic Drugs: The Classical Mean Dose Method
Leucht, S., Samara, M. T., Heres, S., Patel, M. X., Furukawa, T. A., Cipriani, A., Geddes, J. R., & Davis, J. M. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv037 · Cited by 321 · see citing works
An integrative perspective on the role of dopamine in schizophrenia
Maia, T. V., & Frank, M. J. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.05.021 · Cited by 293 · see citing works
Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia
Leucht, S., Crippa, A., Siafis, S., Patel, M. X., Orsini, N., & Davis, J. M. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010034 · Cited by 301 · see citing works
Self-citationEfficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia
Samara, M. T., Dold, M., Gianatsi, M., Nikolakopoulou, A., Helfer, B., Salanti, G., & Leucht, S. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2955 · Cited by 305 · see citing works
Maintenance treatment with antipsychotic drugs for schizophrenia
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., & Davis, J. M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008016.pub2 · Cited by 287 · see citing works
Rummel‐Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Kissling, W., Davis, J. M., & Leucht, S. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq042 · Cited by 272 · see citing works
Correll, C. U. (2010) · European Psychiatry · doi:10.1016/s0924-9338(10)71701-6 · Cited by 272 · see citing works
Citrome, L. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02228.x · Cited by 266 · see citing works
Increasing placebo responses over time in U.S. clinical trials of neuropathic pain
Tuttle, A. H., Tohyama, S., Ramsay, T., Kimmelman, J., Schweinhardt, P., Bennett, G. J., & Mogil, J. S. (2015) · Pain · doi:10.1097/j.pain.0000000000000333 · Cited by 262 · see citing works
Clinical predictors of therapeutic response to antipsychotics in schizophrenia
Carbon, M., & Correll, C. U. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.4/mcarbon · Cited by 257 · see citing works
A systematic review of the evidence of clozapine's anti-aggressive effects
Frogley, C. L., Taylor, D. M., Dickens, G. L., & Picchioni, M. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114571100201x · Cited by 256 · see citing works
Efficacy of Antimanic Treatments: Meta-analysis of Randomized, Controlled Trials
Yıldız, A., Vieta, E., Leucht, S., & Baldessarini, R. J. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.192 · Cited by 251 · see citing works
Past and Present Progress in the Pharmacologic Treatment of Schizophrenia
Kane, J. M., & Correll, C. U. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10r06264yel · Cited by 232 · see citing works
Krause, M., Zhu, Y., Huhn, M., Schneider‐Thoma, J., Bighelli, I., Nikolakopoulou, A., & Leucht, S. (2018) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-018-0869-3 · Cited by 234 · see citing works
Secondary negative symptoms — A review of mechanisms, assessment and treatment
Kirschner, M., Aleman, A., & Kaiser, S. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.05.003 · Cited by 215 · see citing works
Young, S. L., Taylor, M., & Lawrie, S. M. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114562090 · Cited by 212 · see citing works
Nitta, M., Kishimoto, T., Müller, N., Weiser, M., Davidson, M., Kane, J. M., & Correll, C. U. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt070 · Cited by 204 · see citing works
Cognitive-behavioral therapy for medication-resistant psychosis: A meta-analytic review
Burns, A. M. N., Erickson, D. H., & Brenner, C. A. (2014) · Psychiatric Services · doi:10.1176/appi.ps.201300213 · Cited by 199 · see citing works
Network meta-analyses should be the highest level of evidence in treatment guidelines
Leucht, S., Chaimani, A., Cipriani, A. S., Davis, J. M., Furukawa, T. A., & Salanti, G. (2016) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-016-0715-4 · Cited by 202 · see citing works
Self-citationBlanchard, J. J., Kring, A. M., Horan, W. P., & Gur, R. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq104 · Cited by 239 · see citing works
The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia
GOFF, D. C., Falkai, P., Fleischhacker, W. W., Girgis, R. R., Kahn, R. S., Uchida, H., Zhao, J., & Lieberman, J. A. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16091016 · Cited by 194 · see citing works
Quetiapine versus typical antipsychotic medications for schizophrenia
Suttajit, S., Srisurapanont, M., Xia, J., Suttajit, S., Maneeton, B., & Maneeton, N. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007815.pub2 · Cited by 192 · see citing works
Further evidence for the efficacy of a metacognitive group training in schizophrenia
Moritz, S., Kerstan, A., Veckenstedt, R., Randjbar, S., Vitzthum, F., Schmidt, C. S., Heise, M., & Woodward, T. S. (2010) · Behaviour Research and Therapy · doi:10.1016/j.brat.2010.11.010 · Cited by 194 · see citing works
Cognitive behavioural therapy for psychosis prevention: a systematic review and meta-analysis
Hutton, P., & Taylor, P. J. (2014) · Psychological Medicine · doi:10.1017/s0033291713000354 · Cited by 184 · see citing works
Kishimoto, T., Hagi, K., Nitta, M., Leucht, S., Olfson, M., Kane, J. M., & Correll, C. U. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx090 · Cited by 186 · see citing works
Patel, C. A., Émond, B., Lafeuille, M., Côté‐Sergent, A., Lefèbvre, P., Tandon, N., & Khoury, A. C. E. (2019) · Drugs - Real World Outcomes · doi:10.1007/s40801-019-00172-9 · Cited by 185 · see citing works
Efficacy and safety of clozapine in psychotic disorders—a systematic quantitative meta-review
Wagner, E. M., Siafis, S., Fernando, P., Falkai, P., Honer, W. G., Roeh, A., Siskind, D. J., Leucht, S., & Hasan, A. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01613-2 · Cited by 185 · see citing works
Caemmerer, J., Correll, C. U., & Maayan, L. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.03.017 · Cited by 182 · see citing works
Detecting and defusing cognitive traps: metacognitive intervention in schizophrenia
Moritz, S., Vitzthum, F., Randjbar, S., Veckenstedt, R., & Woodward, T. S. (2010) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32833d16a8 · Cited by 182 · see citing works
Pharmacologic treatment of schizophrenia
Kane, J. M., & Correll, C. U. (2010) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2010.12.3/jkane · Cited by 178 · see citing works
Maintenance treatment with antipsychotic drugs for schizophrenia
Ceraso, A., Lin, J., Schneider‐Thoma, J., Siafis, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Davis, J. M., & Leucht, S. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008016.pub3 · Cited by 176 · see citing works
Abraha, I., Cherubini, A., Cozzolino, F., De Florio, R., Luchetta, M. L., Rimland, J. M., Folletti, I., Marchesi, M., Germani, A., Orso, M., et al. (2015) · BMJ · doi:10.1136/bmj.h2445 · Cited by 165 · see citing works
Benzodiazepines for schizophrenia
Dold, M., Li, C., Tardy, M., Khorsand, V., Gillies, D. M., & Leucht, S. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006391.pub2 · Cited by 169 · see citing works
Lilienfeld, S. O., Ritschel, L. A., Lynn, S. J., Cautin, R. L., & Latzman, R. D. (2014) · Perspectives on Psychological Science · doi:10.1177/1745691614535216 · Cited by 191 · see citing works
Cariprazine in Acute Exacerbation of Schizophrenia
Durgam, S., Cutler, A. J., Lu, K., Migliore, R., Ruth, A., Laszlovszky, I., Németh, G., & Meltzer, H. Y. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m09997 · Cited by 167 · see citing works
Ralph, S. J., & Espinet, A. J. (2018) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-170042 · Cited by 160 · see citing works
Second-generation antipsychotics for schizophrenia: can we resolve the conflict?
Leucht, S., Kissling, W., & Davis, J. M. (2009) · Psychological Medicine · doi:10.1017/s0033291709005455 · Cited by 156 · see citing works
Moritz, S., Veckenstedt, R., Randjbar, S., Vitzthum, F., & Woodward, T. S. (2011) · Psychological Medicine · doi:10.1017/s0033291710002618 · Cited by 158 · see citing works
Kandola, A., Hendrikse, J., Lucassen, P. J., & Yücel, M. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00373 · Cited by 155 · see citing works
“…have recently suggested that the effectiveness of antipsychotic and antidepressant medications is only marginally different from that of a placebo (Leucht et al., 2009; Rief et al., 2009), and neither have been able to successfully remediate cognitive dysfunction (Keefe et al., 2013, 2014; Solé…”
Kemp, A. S., Schooler, N. R., Kalali, A. H., Alphs, L. D., Anand, R., Awad, G. A., Davidson, M., Dubé, S., Ereshefsky, L., Gharabawi, G. M., et al. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn110 · Cited by 151 · see citing works
Complementary group Metacognitive Training (MCT) reduces delusional ideation in schizophrenia.
Moritz, S., Veckenstedt, R., Bohn, F., Hottenrott, B., Scheu, F., Randjbar, S., Aghotor, J., Köther, U., Woodward, T. S., Treszl, A., et al. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.10.007 · Cited by 146 · see citing works
Second-generation antipsychotics and constipation: A review of the literature
Hert, M. D., Hudyana, H., Dockx, L., Bernagie, C., Sweers, K., Tack, J. F., Leucht, S., & Peuskens, J. (2010) · European Psychiatry · doi:10.1016/j.eurpsy.2010.03.003 · Cited by 148 · see citing works
Self-Evaluation of Negative Symptoms: A Novel Tool to Assess Negative Symptoms
Dollfus, S., Mach, C., & Morello, R. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv161 · Cited by 148 · see citing works
Jansen, J. E., Gleeson, J., Bendall, S., Rice, S., & Alvarez-Jimenez, M. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2019.11.016 · Cited by 144 · see citing works
Birchwood, M. J., Michail, M., Meaden, A., Tarrier, N., Lewis, S. W., Wykes, T., Davies, L. M., Dunn, G., & PETERS, E. R. (2014) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)70247-0 · Cited by 146 · see citing works
Revisiting the therapeutic effect of rTMS on negative symptoms in schizophrenia: A meta-analysis
Shi, C., Yu, X., Cheung, E. F. C., Shum, D., & Chan, R. C. K. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.12.019 · Cited by 144 · see citing works
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J. A., Glenthoj, B. Y., Gattaz, W. F., Thibaut, F., Möller, H., & on behalf of the WFSBP Task Force on Treatment Guidelines for Schizophrenia (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2015.1009163 · Cited by 146 · see citing works
Meta-Regression Analysis of Placebo Response in Antipsychotic Trials, 1970–2010
Agid, O., SIU, C. O., Potkin, S. G., Kapur, S., Watsky, E. J., Vanderburg, D. G., Zipursky, R. B., & Remington, G. J. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12030315 · Cited by 140 · see citing works
Hartling, L., Abou-Setta, A. M., Dursun, S. M., Mousavi, S. S., Pasichnyk, D., & Newton, A. S. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-7-201210020-00525 · Cited by 140 · see citing works
Klingberg, S., Wölwer, W., Engel, C., Wittorf, A., Herrlich, J., Meisner, C., Buchkremer, G., & Wiedemann, G. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr073 · Cited by 140 · see citing works
Statins and Inflammation: New Therapeutic Opportunities in Psychiatry
Kim, S., Kang, H., Jhon, M., Kim, J., Lee, J., Walker, A. J., Agustini, B., Kim, J., & Berk, M. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00103 · Cited by 137 · see citing works
Citrome, L. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02587.x · Cited by 130 · see citing works
Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials
Wu, H., Siafis, S., Hamza, T., Schneider‐Thoma, J., Davis, J. M., Salanti, G., & Leucht, S. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac001 · Cited by 131 · see citing works
Kishimoto, T., Hagi, K., Nitta, M., Kane, J. M., & Correll, C. U. (2019) · World Psychiatry · doi:10.1002/wps.20632 · Cited by 131 · see citing works
Antipsychotics: is it time to introduce patient choice?
Morrison, A. P., Hutton, P., Shiers, D., & Turkington, D. (2012) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.112.112110 · Cited by 126 · see citing works
Pawełczyk, T., Grancow-Grabka, M., Kotlicka‐Antczak, M., Trafalska, E., & Pawełczyk, A. M. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.11.013 · Cited by 117 · see citing works
Joining psychiatric care and faith healing in a prayer camp in Ghana: randomised trial
Ofori-Atta, A. L., Attafuah, J., Jack, H. E., Baning, F., & Rosenheck, R. A. (2018) · The British Journal of Psychiatry · doi:10.1192/bjp.2017.12 · Cited by 117 · see citing works
Takeuchi, H., Suzuki, T., Uchida, H., Watanabe, K., & Mimura, M. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2011.11.021 · Cited by 115 · see citing works
Forbes, C. B., Blanchard, J. J., Bennett, M. E., Horan, W. P., Kring, A. M., & Gur, R. E. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.08.039 · Cited by 115 · see citing works
How effective are common medications: a perspective based on meta-analyses of major drugs
Leucht, S., Helfer, B., Gartlehner, G., & Davis, J. M. (2015) · BMC Medicine · doi:10.1186/s12916-015-0494-1 · Cited by 115 · see citing works
Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study
Ogasa, M., Kimura, T., Nakamura, M., & Guarino, J. J. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2838-2 · Cited by 114 · see citing works
Moritz, S., Favrod, J., Andreou, C., Morrison, A. P., Bohn, F., Veckenstedt, R., Tonn, P., & Karow, A. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs005 · Cited by 112 · see citing works
Leucht, S., Priller, J., & Davis, J. M. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240738 · Cited by 117 · see citing works
Turner, E. H., Knoepflmacher, D., & Shapley, L. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001189 · Cited by 106 · see citing works
Evidence-based pharmacotherapy of schizophrenia
Leucht, S., Heres, S., Kissling, W., & Davis, J. M. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001380 · Cited by 102 · see citing works
Antipsychotic treatment of schizophrenia: An update
Bruijnzeel, D. M., Suryadevara, U., & Tandon, R. (2014) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2014.08.002 · Cited by 101 · see citing works
Cognitive behavioral therapy for negative symptoms (CBT-n) in psychotic disorders: A pilot study
Staring, A. B. P., ter Huurne, M.-A. B., & van der Gaag, M. (2013) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/j.jbtep.2013.01.004 · Cited by 95 · see citing works
Citrome, L. (2013) · CNS Drugs · doi:10.1007/s40263-013-0105-7 · Cited by 94 · see citing works
Structural and functional imaging markers for susceptibility to psychosis
Andreou, C., & Borgwardt, S. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0679-7 · Cited by 94 · see citing works
Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review
Veerman, S. R. T., Schulte, P. F. J., & de Haan, L. (2017) · Drugs · doi:10.1007/s40265-017-0789-y · Cited by 96 · see citing works
Packages of Care for Schizophrenia in Low- and Middle-Income Countries
Mari, J. D. J., Razzouk, D., Thara, R., Eaton, J., & Thornicroft, G. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000165 · Cited by 91 · see citing works
Zeng, J., Yan, J., Cao, H., Su, Y., Song, Y. Y., Luo, Y., & Yang, X. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02201-8 · Cited by 84 · see citing works
Morrison, A. P., Law, H., Carter, L., Sellers, R., Emsley, R., Pyle, M., French, P., Shiers, D., Yung, A. R., Murphy, E., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30096-8 · Cited by 85 · see citing works
New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia
Citrome, L. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.811984 · Cited by 81 · see citing works
The expanding role of somatostatin analogs in the management of neuroendocrine tumors.
Wolin, E. M. (2012) · Europe PMC (PubMed Central) · Cited by 81 · see citing works
Read, J., & Williams, J. (2019) · Current Drug Safety · doi:10.2174/1574886314666190301152734 · Cited by 80 · see citing works
- Authors
- Leucht, S., Arbter, D., Engel, R. R., Kissling, W., & Davis, J. M.
- Affiliations
- TUM Klinikum (DE)
- Ludwig-Maximilians-Universität München (DE)
- University of Illinois Chicago (US)
- Corresponding author
- Leucht, S
- Venue
- Molecular Psychiatry
- Published
- 2008-01-08
- Volume
- 14
- Issue
- 4
- Pages
- 429-447
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2021186654
- Cited by
- 489
- References
- 77
- Citations by year
- 2026: 5 · 2025: 13 · 2024: 15 · 2023: 17 · 2022: 20 · 2021: 23 · 2020: 24 · 2019: 36 · 2018: 32 · 2017: 35 · 2016: 38 · 2015: 36 · 2014: 48 · 2013: 35 · 2012: 34
- FWCI
- 3.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Keywords
- atypical antipsychotics, schizophrenia, drug efficacy, haloperidol, negative symptoms, positive symptoms, depressive symptoms, relapse, extrapyramidal symptoms, adverse events, treatment response over time, publication bias
- MeSH terms
- Humans, Psychotic Disorders, Antipsychotic Agents, Randomized Controlled Trials as Topic, MEDLINE, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review